Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT 1 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT 1 COMBINATION PACK.
AMPHOTERICIN B vs MONISTAT 1 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%.
Category C
Category C
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."